141 related articles for article (PubMed ID: 2378547)
1. Fluphenazine dose, clinical response, and extrapyramidal symptoms during acute treatment.
Levinson DF; Simpson GM; Singh H; Yadalam K; Jain A; Stephanos MJ; Silver P
Arch Gen Psychiatry; 1990 Aug; 47(8):761-8. PubMed ID: 2378547
[TBL] [Abstract][Full Text] [Related]
2. Fluphenazine plasma levels, dosage, efficacy, and side effects.
Levinson DF; Simpson GM; Lo ES; Cooper TB; Singh H; Yadalam K; Stephanos MJ
Am J Psychiatry; 1995 May; 152(5):765-71. PubMed ID: 7726317
[TBL] [Abstract][Full Text] [Related]
3. Acute dystonia during fixed-dose neuroleptic treatment.
Singh H; Levinson DF; Simpson GM; Lo ES; Friedman E
J Clin Psychopharmacol; 1990 Dec; 10(6):389-96. PubMed ID: 2286708
[TBL] [Abstract][Full Text] [Related]
4. A double-blind dose-reduction trial of fluphenazine decanoate for chronic, unstable schizophrenic patients.
Inderbitzin LB; Lewine RR; Scheller-Gilkey G; Swofford CD; Egan GJ; Gloersen BA; Vidanagama BP; Waternaux C
Am J Psychiatry; 1994 Dec; 151(12):1753-9. PubMed ID: 7977881
[TBL] [Abstract][Full Text] [Related]
5. Relation of plasma fluphenazine levels to treatment response and extrapyramidal side effects in first-episode schizophrenic patients.
Koreen AR; Lieberman J; Alvir J; Chakos M; Loebel A; Cooper T; Kane J
Am J Psychiatry; 1994 Jan; 151(1):35-9. PubMed ID: 8267132
[TBL] [Abstract][Full Text] [Related]
6. Controlled, dose-response study of sertindole and haloperidol in the treatment of schizophrenia. Sertindole Study Group.
Zimbroff DL; Kane JM; Tamminga CA; Daniel DG; Mack RJ; Wozniak PJ; Sebree TB; Wallin BA; Kashkin KB
Am J Psychiatry; 1997 Jun; 154(6):782-91. PubMed ID: 9167505
[TBL] [Abstract][Full Text] [Related]
7. Comparison of the incidence and severity of extrapyramidal side effects with fluphenazine enanthate and fluphenazine decanoate.
Kane J; Quitkin F; Rifkin A; Klein DF
Am J Psychiatry; 1978 Dec; 135(12):1539-42. PubMed ID: 717574
[TBL] [Abstract][Full Text] [Related]
8. Olanzapine versus fluphenazine in an open trial in patients with psychotic combat-related post-traumatic stress disorder.
Pivac N; Kozaric-Kovacic D; Muck-Seler D
Psychopharmacology (Berl); 2004 Oct; 175(4):451-6. PubMed ID: 15064916
[TBL] [Abstract][Full Text] [Related]
9. First generation antipsychotics switch with Risperidone in the treatment of chronic schizophrenic patients.
Popović I; Ravanić D; Popović V; Vladejić S; Stanojević A; Stojanović M
Psychiatr Danub; 2011 Dec; 23(4):384-8. PubMed ID: 22075740
[TBL] [Abstract][Full Text] [Related]
10. Fluphenazine enanthate and fluphenazine decanoate in the treatment of schizophrenic outpatients: extrapyramidal symptoms and therapeutic effect.
Chouinard G; Annable L; Ross-Chouinard A
Am J Psychiatry; 1982 Mar; 139(3):312-8. PubMed ID: 6120655
[No Abstract] [Full Text] [Related]
11. Acute extrapyramidal reactions with fluphenazine hydrochloride and fluphenazine decanoate.
Gelenberg AJ; Doller JC; Schooler NR; Mieske M; Severe J; Mandel MR
Am J Psychiatry; 1979 Feb; 136(2):217-9. PubMed ID: 367182
[No Abstract] [Full Text] [Related]
12. Timing of acute clinical response to fluphenazine.
Levinson DF; Singh H; Simpson GM
Br J Psychiatry; 1992 Mar; 160():365-71. PubMed ID: 1562863
[TBL] [Abstract][Full Text] [Related]
13. A randomized double-blind study of risperidone and olanzapine in the treatment of schizophrenia or schizoaffective disorder.
Conley RR; Mahmoud R
Am J Psychiatry; 2001 May; 158(5):765-74. PubMed ID: 11329400
[TBL] [Abstract][Full Text] [Related]
14. Phenothiazine-induced decompensation.
Van Putten T; Mutalipassi LR; Malkin MD
Arch Gen Psychiatry; 1974 Jan; 30(1):102-5. PubMed ID: 4587065
[No Abstract] [Full Text] [Related]
15. Incidence and correlates of acute extrapyramidal symptoms in first episode of schizophrenia.
Chakos MH; Mayerhoff DI; Loebel AD; Alvir JM; Lieberman JA
Psychopharmacol Bull; 1992; 28(1):81-6. PubMed ID: 1609046
[TBL] [Abstract][Full Text] [Related]
16. Plasma levels of fluphenazine in patients receiving fluphenazine decanoate. Relationship to clinical response.
Marder SR; Midha KK; Van Putten T; Aravagiri M; Hawes EM; Hubbard JW; McKay G; Mintz J
Br J Psychiatry; 1991 May; 158():658-65. PubMed ID: 1860020
[TBL] [Abstract][Full Text] [Related]
17. Depot fluphenazine: risk/benefit ratio.
Glazer WM
J Clin Psychiatry; 1984 May; 45(5 Pt 2):28-35. PubMed ID: 6370986
[TBL] [Abstract][Full Text] [Related]
18. Depressive and extrapyramidal symptoms and clinical effects: a trial of fluphenazine versus flupenthixol in maintenance of schizophrenic out-patients.
Knights A; Okasha MS; Salih MA; Hirsch SR
Br J Psychiatry; 1979 Dec; 135():515-23. PubMed ID: 394794
[TBL] [Abstract][Full Text] [Related]
19. The relationship between blood perphenazine levels, early resolution of psychotic symptoms, and side effects.
Mazure CM; Nelson JC; Jatlow PI; Kincare P; Bowers MB
J Clin Psychiatry; 1990 Aug; 51(8):330-4. PubMed ID: 2199431
[TBL] [Abstract][Full Text] [Related]
20. Treatment of schizophrenia with depot preparations of fluphenazine, haloperidol, and risperidone among inpatients at state-operated psychiatric facilities.
Citrome L; Jaffe A; Levine J
Schizophr Res; 2010 Jun; 119(1-3):153-9. PubMed ID: 20347267
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
